John E. Flaherty
Jonathan M. H. Short

McCarter & English, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
T (973) 622-4444
F (973) 624-7070

Attorneys for all Plaintiffs

Of Counsel:

Eric J. Lobenfeld HOGAN LOVELLS HORITSU

Arlene L. Chow **JIMUSHO**

Dillon Kim

HOGAN LOVELLS US LLP

875 Third Avenue

New York, New York 10022

Gaikokuho Kyodo Jigyo

15th Floor Daido Seimei

Kasumigaseki Building

1-4-2 Kasumigaseki

(212) 918-3000 Chiyoda-ku, Tokyo 100-0013 Japan

(81) 3-5157-8200

Philippe Y. Riesen

Attorneys for all Plaintiffs

Attorney for all Plaintiffs

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

TAKEDA PHARMACEUTICAL
COMPANY LIMITED, TAKEDA
PHARMACEUTICALS NORTH AMERICA,
INC., TAKEDA PHARMACEUTICALS
LLC, TAKEDA PHARMACEUTICALS
AMERICA, INC., and ETHYPHARM, S.A.,

Plaintiffs and Counterclaim-Defendants,

v.

ZYDUS PHARMACEUTICALS (USA) INC. and CADILA HEALTHCARE LIMITED,

Defendants and Counterclaim-Plaintiffs.

Civil Action No. 3:10-CV-01723-JAP-TJB

MEMORANDUM IN SUPPORT OF TAKEDA'S MOTION FOR SPOLIATION SANCTIONS IN THE FORM OF EXCLUSION OF ZYDUS' EVIDENCE OF PARTICLE SIZE TESTING ON PRE-TABLETED GRANULES

> CONFIDENTIAL – TO BE FILED UNDER SEAL

TABLE OF CONTENTS

	Page
PRELIMINARY STATEMENT	1
STATEMENT OF FACTS	3
A. The Takeda Patents-in-Suit Incorporate a Particle Size Requirement for Granules	3
В.	
	3
C.	4
D.	
	6
E.	
	7
ARGUMENT	
A	
	7
B. Exclusion of Zydus' Evidence of Particle Size Testing of Pre-Tableted Granules Is the Appropriate Sanction	8
CONCLUSION	10

TABLE OF AUTHORITIES

Cases	Page(s)
Katiroll Co., Inc. v. Kati Roll and Platters, Inc., Civil Action No. 10-3620 (GEB), 2011 WL 3583408 (D.N.J. Aug. 3, 2011)	7
Mosaid Techs. Inc. v. Samsung Elecs. Co., Ltd., 348 F. Supp. 2d 332 (D.N.J. 2004)	7, 8, 9
Quaglietta v. Nissan Motor Co., Ltd., No. Civ. A. 97-5965, 2000 WL 1306791 (D.N.J. Aug. 16, 2000), aff'd, 281 F.3 (3d Cir. 2002)	

The Takeda Plaintiffs¹ ("Takeda") submit this memorandum in support of their motion for spoliation sanctions against Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (together, "Zydus").

PRELIMINARY STATEMENT

This is a patent infringement action under the Hatch-Waxman Act in relation to						
Prevacid [®] SoluTab™, Takeda's orally disintegrating tablet ("ODT") formulation of its						
blockbuster drug Prevacid®. The three Takeda patents-in-suit² require the claimed ODT to						
include, among other things, enteric coated granules of specified particle sizes ("particle size						
requirements").						

¹ The Takeda Plaintiffs are Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, and Takeda Pharmaceuticals America, Inc.

 $^{^2}$ U.S. Patent Nos. 6,328,994 (the "'994 patent"), 7,431,942 (the "'942 patent), 7,875,292 (the "'292 patent").

(See Ex. 1, 2/17/12 e-mail from
S. Moore to A. Chow).


Zydus' gamesmanship should not be countenanced by the Court. Zydus should not be
permitted to benefit from evidence in its sole possession, custody and control that it destroyed or
has made otherwise unavailable.
has made otherwise unavariable.


STATEMENT OF FACTS


A. The Takeda Patents-in-Suit Incorporate a Particle Size Requirement for Granules


The Takeda patents-in-suit are directed toward a novel orally disintegrating tablet formulation containing fine lansoprazole microgranules. Upon disintegration of the tablet, these small granules remain in the mouth so that they can be easily swallowed. Specifically, the '994 patent claims "fine granules" that have "an average particle diameter of 400 μ m or less." This Court construed this term to mean "fine granules up to and including the enteric coating layer having an average particle diameter of 400 μ m (\pm 10%) or less." (D.I. 113). The '942 and '292 patent claims are similar to that of the '994 patent, except that the "fine granules" include a mannitol coating layer on top of the enteric coated granule. Further, the '942 and '292 patents require that the "average particle diameter" of the "fine granules" be "300 to 400 μ m" and "400 μ m or less," respectively. Based on the same considerations as the '994 patent, this Court construed the '942 patent as also incorporating a measurement variation of \pm 10% (D.I. 113); the parties stipulated that claim construction of the '994 and '942 patents would control claim construction of the '292 patent. (D.I. 97).

В.			










ARGUMENT

A.

"Spoliation is 'the destruction or significant alteration of evidence, or the failure to preserve property for another's use as evidence in pending or reasonably foreseeable litigation.""

Mosaid Techs. Inc. v. Samsung Elecs. Co., Ltd., 348 F. Supp. 2d 332, 335 (D.N.J. 2004) (citation omitted). The duty to preserve relevant litigation evidence 'arises when the party in possession of the evidence knows that litigation by the party seeking the evidence is pending or probable and the party in possession of the evidence can foresee the harm or prejudice that would be caused to the party seeking the evidence if the evidence were to be discarded.' Katiroll Co., Inc. v. Kati Roll and Platters, Inc., Civil Action No. 10-3620 (GEB), 2011 WL 3583408, *1 (D.N.J. Aug. 3, 2011) (citation omitted).




"Spoliation sanctions serve a remedial function by leveling the playing field or restoring the prejudiced party to the position it would have been without spoliation. They also serve a punitive function, by punishing the spoliator for its actions, and a deterrent function, by sending a clear message to other potential litigants that this type of behavior will not be tolerated and will be dealt with appropriately if need be." *Mosaid*, 348 F. Supp. 2d at 335. Spoliation sanctions include: dismissal of a claim or granting judgment in favor of a prejudiced party; suppression of evidence; an adverse inference (*i.e.*, the spoliation inference); fines; and attorney's fees and costs. *Mosaid*, 348 F. Supp. 2d at 335.

In determining whether sanctions such as exclusion of evidence are warranted, the Court considers: '(1) the degree of fault of the party who altered or destroyed the evidence; (2) the degree of prejudice suffered by the opposing party; and (3) whether there is a lesser sanction that will avoid substantial unfairness to the opposing party and, where the offending party is seriously at fault, will serve to deter such conduct by others in the future.' *Id.* (citation omitted).

Compared to dismissal, this Court has described the sanction of excluding evidence to be "[a] lesser sanction, but an effective one because it can put the parties on a level playing field and deter future discovery violations." *Quaglietta v. Nissan Motor Co., Ltd.*, No. Civ. A. 97-5965, 2000 WL 1306791, *2 (D.N.J. Aug. 16, 2000), *aff'd*, 281 F.3d 223 (3d Cir. 2002).

Exclusion of evide	ence is warranted here.			
William V				
			- 7	
	200			(imme
	W.I.			
			0.00	
	100004			
		11000		
		2000		
	WING			

			21-110092	
			1300	



CONCLUSION

For the foregoing reasons, Takeda respectfully requests that this Court exclude Zydus' evidence of particle size testing of pre-tableted granules.

Dated: February 21, 2012

Respectfully submitted,

By: s/John E. Flaherty
John E. Flaherty
Jonathan M.H. Short
McCarter & English, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

Attorneys for all Plaintiffs

OF COUNSEL: Eric J. Lobenfeld Arlene L. Chow Dillon Kim HOGAN LOVELLS US LLP 875 Third Avenue New York, New York 10022 (212) 918-3000

Philippe Y. Riesen

HOGAN LOVELLS HORITSU JIMUSHO Gaikokuho Kyodo Jigyo 15th Floor Daido Seimei Kasumigaseki Building 1-4-2 Kasumigaseki Chiyoda-ku, Tokyo 100-0013 Japan (81) 3-5157-8200

Attorneys for all Plaintiffs